Terns Ebitda from 2010 to 2024

TERN Stock  USD 6.70  0.22  3.18%   
Terns Pharmaceuticals EBITDA yearly trend continues to be very stable with very little volatility. EBITDA is likely to grow to about -97.4 M this year. During the period from 2010 to 2024, Terns Pharmaceuticals EBITDA quarterly data regression pattern had range of 84.2 M and standard deviation of  30,277,178. View All Fundamentals
 
EBITDA  
First Reported
2019-12-31
Previous Quarter
-25.3 M
Current Value
-24.7 M
Quarterly Volatility
7.2 M
 
Covid
Check Terns Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Terns Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 335.7 K, Net Interest Income of 13.5 M or Interest Income of 13.5 M, as well as many indicators such as Price To Sales Ratio of 143, Dividend Yield of 0.0 or PTB Ratio of 1.72. Terns financial statements analysis is a perfect complement when working with Terns Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Terns Pharmaceuticals Correlation against competitors.
To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.

Latest Terns Pharmaceuticals' Ebitda Growth Pattern

Below is the plot of the Ebitda of Terns Pharmaceuticals over the last few years. It is Terns Pharmaceuticals' EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Terns Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

Terns Ebitda Regression Statistics

Arithmetic Mean(38,831,740)
Coefficient Of Variation(77.97)
Mean Deviation24,823,520
Median(18,390,000)
Standard Deviation30,277,178
Sample Variance916.7T
Range84.2M
R-Value(0.82)
Mean Square Error324.6T
R-Squared0.67
Significance0.0002
Slope(5,546,795)
Total Sum of Squares12833.9T

Terns Ebitda History

2024-97.4 M
2023-102.6 M
2022-61 M
2021-49.3 M
2020-36.6 M
2019-70 M

About Terns Pharmaceuticals Financial Statements

Terns Pharmaceuticals investors utilize fundamental indicators, such as Ebitda, to predict how Terns Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
EBITDA-102.6 M-97.4 M

Pair Trading with Terns Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Terns Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Terns Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Terns Stock

  0.71JNJ Johnson Johnson Fiscal Year End 28th of January 2025 PairCorr
  0.74LLY Eli LillyPairCorr

Moving against Terns Stock

  0.85BMY Bristol Myers SquibbPairCorr
  0.74GILD Gilead SciencesPairCorr
  0.62ESPR Esperion TherapeuticsPairCorr
  0.62XAIR Beyond AirPairCorr
  0.6CAH Cardinal HealthPairCorr
The ability to find closely correlated positions to Terns Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Terns Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Terns Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Terns Pharmaceuticals to buy it.
The correlation of Terns Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Terns Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Terns Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Terns Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Terns Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Terns Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Terns Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Terns Pharmaceuticals Stock:
Check out the analysis of Terns Pharmaceuticals Correlation against competitors.
To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Terns Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.18)
Revenue Per Share
0.035
Return On Assets
(0.19)
Return On Equity
(0.28)
The market value of Terns Pharmaceuticals is measured differently than its book value, which is the value of Terns that is recorded on the company's balance sheet. Investors also form their own opinion of Terns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Terns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Terns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Terns Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Terns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.